JD Supra Law

JANUARY 11, 2023

AbbVie Inc. On 21 July 2022, the Third Circuit in Perrigo Co. affirmed the district court’s judgment that the mutual release in the settlement agreement between the parties from an earlier patent infringement and Hatch-Waxman Act litigation barred plaintiffs’ subsequent antirust claim. By: K&L Gates LLP

Settlement 55

Settlement Patent Infringement Litigation Patent 55

IP Law 360

NOVEMBER 29, 2023

Judges on a Third Circuit panel were skeptical Wednesday of arguments from AbbVie Inc. that a lower court's ruling on discovery of attorney communications in a "sham" patent case would open the floodgates to privilege challenges any time a drug company files a suit that slows down a competitor.

Patent 52

Patent 52

JD Supra Law

SEPTEMBER 23, 2021

s motion to dismiss AbbVie’s biosimilar lawsuit involving its blockbuster arthritis drug, Humira. AbbVie Inc. AbbVie filed the lawsuit against Alvotech hf. an Icelandic company, is not named as the applicant for. District Court for the Northern District of Illinois denied Alvotech hf.’s Alvotech HF, No.

Patent 97

Patent 97

IP Law 360

FEBRUARY 22, 2024

The Third Circuit has denied AbbVie Inc.'s s bid to block a Pennsylvania federal court's order to turn over attorney communications from a patent case allegedly cooked up just to extend the company's monopoly on a testosterone drug, but the appellate court's explanation remained under seal Thursday.

Patent 40

Patent 40

IP Law 360

NOVEMBER 1, 2023

The Patent Trial and Appeal Board has canceled every claim in an AbbVie Inc. patent for a method of treating Parkinson's disease, but then rejected all the substitute claims proposed by the pharmaceutical company.

Patent 45

Patent 45

LexBlog IP

OCTOBER 25, 2021

In March 2021, AbbVie, Inc. and AbbVie Biotechnology Ltd. (“AbbVie”) sued rival pharmaceutical company Alvotech hf. (“Alvotech”) for trade secret misappropriation under the federal Defend Trade Secrets Act (“DTSA”) and the Illinois Trade Secret Act.

Intellectual Property 52

Intellectual Property Business Litigation Marketing 52

Bio Law Blog

SEPTEMBER 21, 2021

’s motion to dismiss AbbVie’s biosimilar lawsuit involving its blockbuster arthritis drug, Humira. AbbVie Inc. AbbVie filed the lawsuit against Alvotech hf. AbbVie filed the lawsuit against Alvotech hf. AbbVie identified 62 patents that would be infringed by the proposed biosimilar product.

Marketing 52

Marketing Marketing Litigation Patent 52